Compare DraftKings Inc (DKNG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs IDEXX Laboratories, Inc. — how do they compare? DraftKings Inc trades at $19.37 (market cap $9.86B), while IDEXX Laboratories, Inc. trades at $519.9 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.1× DraftKings Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 16,584,596). Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DKNG | IDXX | |
|---|---|---|
Market Cap | $9.86B | $40.43B |
Volume | 16,584,596 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $766.68 |
52-Week Low | $18.59 | $504.70 |
Typical Hold Time | 55 Days | 46 Days |
Enterprise Value | $10.80B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.43, down 1.46% on the day and near 52-week lows. The technical picture is bearish with weak moving averages, while fundamentals show strong revenue growth to $6.05B in 2025 but negative profitability metrics. Recent earnings misses and high valuation multiples create headwinds, though analyst sentiment remains overwhelmingly bullish with a $33.13 price target.
The stock faces near-term pressure from technical weakness and earnings volatility, but long-term prospects are supported by market share leadership and prediction platform expansion. Key risks include competitive threats, regulatory uncertainty, and the sustainability of current valuation levels amid profitability challenges.
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
